Classification: Pharmaceutical
Cas NO.: 763113-22-0
Molecular Formula: C24H23FN4O3
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by scientists at the University of Sheffield, KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.